Annual ROE
-131.37%
-58.92%-81.33%
31 December 2023
Summary:
Oncternal Therapeutics annual return on equity is currently -131.37%, with the most recent change of -58.92% (-81.33%) on 31 December 2023. During the last 3 years, it has fallen by -116.12% (-761.44%). ONCT annual ROE is now -284.59% below its all-time high of 71.17%, reached on 31 December 2010.ONCT ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
-177.58%
-41.48%-30.48%
30 September 2024
Summary:
Oncternal Therapeutics quarterly return on equity is currently -177.58%, with the most recent change of -41.48% (-30.48%) on 30 September 2024. Over the past year, it has dropped by -92.29% (-108.21%). ONCT quarterly ROE is now -104.54% below its all-time high of 3915.43%, reached on 31 March 2016.ONCT Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ONCT ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -81.3% | -108.2% |
| 3 y3 years | -761.4% | -619.2% |
| 5 y5 years | +10.7% | -0.3% |
ONCT ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -761.4% | at low | -619.2% | at low |
| 5 y | 5 years | -761.4% | +45.0% | -632.3% | +20.3% |
| alltime | all time | -284.6% | +96.3% | -104.5% | +91.7% |
Oncternal Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -177.58%(+30.5%) |
| June 2024 | - | -136.10%(+26.4%) |
| Mar 2024 | - | -107.67%(+12.3%) |
| Dec 2023 | -131.37%(+81.3%) | -95.87%(+12.4%) |
| Sept 2023 | - | -85.29%(+12.7%) |
| June 2023 | - | -75.67%(+5.8%) |
| Mar 2023 | - | -71.49%(+14.8%) |
| Dec 2022 | -72.45%(+103.7%) | -62.28%(+18.5%) |
| Sept 2022 | - | -52.56%(+12.5%) |
| June 2022 | - | -46.73%(+20.9%) |
| Mar 2022 | - | -38.64%(+21.3%) |
| Dec 2021 | -35.56%(+133.2%) | -31.86%(+29.0%) |
| Sept 2021 | - | -24.69%(+1.8%) |
| June 2021 | - | -24.25%(-18.9%) |
| Mar 2021 | - | -29.91%(-35.5%) |
| Dec 2020 | -15.25%(-93.6%) | -46.35%(-69.2%) |
| Sept 2020 | - | -150.58%(+2.2%) |
| June 2020 | - | -147.33%(-33.8%) |
| Mar 2020 | - | -222.71%(+12.6%) |
| Dec 2019 | -238.88%(+62.4%) | -197.84%(+11.7%) |
| Sept 2019 | - | -177.04%(+2.6%) |
| June 2019 | - | -172.55%(+65.6%) |
| Mar 2019 | - | -104.18%(-17.5%) |
| Dec 2018 | -147.13%(+84.9%) | -126.31%(-0.1%) |
| Sept 2018 | - | -126.39%(+14.2%) |
| June 2018 | - | -110.70%(-13.4%) |
| Mar 2018 | - | -127.88%(+12.9%) |
| Dec 2017 | -79.56%(-10.7%) | -113.26%(-10.0%) |
| Sept 2017 | - | -125.78%(-34.6%) |
| June 2017 | - | -192.46%(+19.7%) |
| Mar 2017 | - | -160.74%(+68.7%) |
| Dec 2016 | -89.11%(-91.1%) | -95.28%(-4.7%) |
| Sept 2016 | - | -99.99%(-143.6%) |
| June 2016 | - | 229.28%(-94.1%) |
| Mar 2016 | - | 3915.43%(+383.7%) |
| Dec 2015 | -1006.08%(+355.1%) | 809.48%(-145.4%) |
| Sept 2015 | - | -1784.48%(-16.7%) |
| June 2015 | - | -2142.91%(+873.6%) |
| Mar 2015 | - | -220.10%(-3.9%) |
| Dec 2014 | -221.05%(-43.9%) | -229.08%(+8.2%) |
| Sept 2014 | - | -211.81%(-1.8%) |
| June 2014 | - | -215.66%(+8.4%) |
| Mar 2014 | - | -198.89%(+4.4%) |
| Dec 2013 | -394.15% | -190.46%(+32.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2013 | - | -143.59%(+95.0%) |
| June 2013 | - | -73.62%(+25.8%) |
| Mar 2013 | - | -58.51%(+19.4%) |
| Dec 2012 | -56.76%(+5.4%) | -48.99%(+11.1%) |
| Sept 2012 | - | -44.11%(-29.1%) |
| June 2012 | - | -62.20%(+13.5%) |
| Mar 2012 | - | -54.82%(+20.8%) |
| Dec 2011 | -53.87%(-175.7%) | -45.39%(+2.9%) |
| Sept 2011 | - | -44.12%(-29.3%) |
| June 2011 | - | -62.43%(-27.8%) |
| Mar 2011 | - | -86.52%(-240.0%) |
| Dec 2010 | 71.17%(-117.9%) | 61.82%(-25.5%) |
| Sept 2010 | - | 82.97%(+41.6%) |
| June 2010 | - | 58.61%(-22.4%) |
| Mar 2010 | - | 75.54%(-118.6%) |
| Dec 2009 | -397.59%(+325.9%) | -407.00%(+82.1%) |
| Sept 2009 | - | -223.54%(+52.8%) |
| June 2009 | - | -146.31%(+28.3%) |
| Mar 2009 | - | -114.07%(+22.4%) |
| Dec 2008 | -93.35%(+103.5%) | -93.22%(+16.8%) |
| Sept 2008 | - | -79.83%(+15.3%) |
| June 2008 | - | -69.21%(+19.7%) |
| Mar 2008 | - | -57.84%(+20.0%) |
| Dec 2007 | -45.87%(+10.2%) | -48.18%(+14.6%) |
| Sept 2007 | - | -42.06%(-6.4%) |
| June 2007 | - | -44.94%(-6.9%) |
| Mar 2007 | - | -48.27%(-9.5%) |
| Dec 2006 | -41.62%(-22.3%) | -53.32%(-25.0%) |
| Sept 2006 | - | -71.10%(+3.0%) |
| June 2006 | - | -69.00%(+0.1%) |
| Mar 2006 | - | -68.90%(+2.3%) |
| Dec 2005 | -53.59%(+53.2%) | -67.38%(+1.4%) |
| Sept 2005 | - | -66.44%(+32.6%) |
| June 2005 | - | -50.11%(+35.0%) |
| Mar 2005 | - | -37.12%(-53.6%) |
| Dec 2004 | -34.97%(-470.1%) | -80.02%(-24.3%) |
| Sept 2004 | - | -105.71%(-90.1%) |
| June 2004 | - | -1066.56%(-2277.5%) |
| Mar 2004 | - | 48.98%(+418.3%) |
| Dec 2003 | 9.45%(-55.9%) | 9.45% |
| Dec 2002 | 21.45%(-9.3%) | - |
| Dec 2001 | 23.66%(+56.2%) | - |
| Dec 2000 | 15.15%(-100.4%) | - |
| Dec 1999 | -3571.43% | - |
FAQ
- What is Oncternal Therapeutics annual return on equity?
- What is the all time high annual ROE for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual ROE year-on-year change?
- What is Oncternal Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly ROE year-on-year change?
What is Oncternal Therapeutics annual return on equity?
The current annual ROE of ONCT is -131.37%
What is the all time high annual ROE for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual return on equity is 71.17%
What is Oncternal Therapeutics annual ROE year-on-year change?
Over the past year, ONCT annual return on equity has changed by -58.92% (-81.33%)
What is Oncternal Therapeutics quarterly return on equity?
The current quarterly ROE of ONCT is -177.58%
What is the all time high quarterly ROE for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly return on equity is 3915.43%
What is Oncternal Therapeutics quarterly ROE year-on-year change?
Over the past year, ONCT quarterly return on equity has changed by -92.29% (-108.21%)